THIS NOTE AND THE INTEREST SHARES AND CONVERSION SHARES, AS DEFINED HEREIN,
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
UNDER ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED
OR OTHERWISE DISPOSED, EXCEPT IN ACCORDANCE WITH THE SECURITIES ACT OF 1933,
AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS.
12% CONVERTIBLE SECURED PROMISSORY NOTE
$1,000,000.00 April __, 2003
FOR VALUE RECEIVED, Molecular Diagnostics, Inc, a Delaware corporation having its principal office at,
414 North Orleans Street, Suite 510, Chicago, Illinois 60610, acting for itself and for all its successors and
assigns, (the "Company") promises to pay to the order of Suzanne M. Gombrich ("Holder"), residing at 57 East
Delaware, Unit 4005, Chicago, Illinois 60611, or at such other place as Holder may from time to time designate
in writing, the principal sum of One Million and 00/100 Dollars (US $1,000,000.00) in the lawful money of the
United States of America, together with interest on so much thereof as is from time to time outstanding at the rate
hereinafter provided, and payable as hereinafter provided.
1. Interest Rate. The unpaid principal balance of this Note shall bear simple interest at the rate of twelve percent
(12%) per annum. Interest shall be payable in cash, quarterly through the Maturity Date (as defined below) on
July 1, 2003, October 1, 2003, January 2, 2004 and April 1, 2004.
2. Maturity Date. The total outstanding principal balance hereof, together with accrued and unpaid interest, shall
be due and payable on the first to occur of the following events ("Triggering Even&'):
(i) the consummation of the Company receiving $4,000,000.00 in equity or other financing and the sale by the
Company of all or a portion of all of the stock or assets of SAMBA Technologies, SARL;
ii) the consummation of the Company receiving $4,000,000.00 in equity or other financing and the sale of an
exclusive worldwide license to the Company'